More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to improve treatment options and patient outcomes. Major pharmaceutical firms like Pfizer, GSK, and United Therapeutics are leading innovations with novel therapies targeting different biological pathways. This surge in clinical research highlights a growing focus on addressing unmet medical needs and advancing PAH treatment globally.
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
